Elahere for ovarian cancer
WebOvarian cancer is a disease in which cancer starts in the cells of the ovary. There are three types of ovarian tumors, each named for the tissue in which they are found: Epithelial … WebFRα is an actionable target with the approval of ELAHERE ™ (mirvetuximab soravtansine-gynx), a FDA-approved FRα—targeting antibody drug conjugate (ADC) for platinum-resistant ovarian cancer. It is important to test all ovarian cancer patients for …
Elahere for ovarian cancer
Did you know?
WebDec 12, 2024 · ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson McKesson Newsroom Press Releases Share ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson December 12, … WebNov 14, 2024 · ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer. Indication Covers Patients with One to Three Prior Systemic Treatment …
WebThe safety of Elahere has been evaluated in a pooled analysis from three studies among a total of 464 patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian … Web1 day ago · As part of the phase 3 GLORIOSA study (NCT05445778), a clinical trial is evaluating the safety and efficacy of the antibody drug conjugate (ADC) mirvetuximab soravtansine (Elahere) as maintenance therapy for patients with folate receptor-alpha (FRα)-positive recurrent platinum-sensitive ovarian cancer. 1 In the multicenter, open …
WebNov 17, 2024 · Elahere, from ImmunoGen, is an antibody-drug conjugate that uses a monoclonal antibody targeting folate receptor alpha (FRα) to deliver a potent chemotherapy drug. It is approved for adults with … Web100mg/20mL (5mg/mL) Ovarian Cancer Indicated for adults with folate receptor–alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who...
WebMar 1, 2024 · ELAHERE™ is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and …
WebNov 14, 2024 · ImmunoGen noted that Elahere is a first-in-class ADC directed against FRα, a cell-surface protein highly expressed in ovarian cancer. It is also the first FDA … moriarty the patriot anime sherlockWebNov 14, 2024 · ImmunoGen ( IMGN) noted that Elahere is a first-in-class ADC directed against FRα, a cell-surface protein highly expressed in ovarian cancer. It is also the first FDA-approved ADC for a... moriarty the patriot bondWebNov 15, 2024 · In the meantime, Elahere, previously known as mirvetuximab soravtansine, can be used to treat ovarian cancer patients whose disease has progressed despite one to three rounds of chemotherapy. Those patients’ tumors must have high levels of a protein called folate receptor alpha. moriarty the patriot anime season 3WebELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum … moriarty the patriot chapter 67moriarty the patriot comic vineWebELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test. moriarty the patriot 76WebNov 14, 2024 · ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin® Use... moriarty the patriot desu online